

## Antibodies

### Anti-Human CD235ab (Glycophorin A/B) Antibody, Clone HIR2, FITC

Mouse monoclonal IgG2b antibody  
against human CD235ab (glycophorin  
A/B), FITC-conjugated

Catalog #60111FI  
#60111FI.1

100 µg 0.5 mg/mL  
25 µg 0.5 mg/mL



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713

INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM

FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

## Product Description

The HIR2 (GA-R2) antibody recognizes an epitope common to the N-terminal region of human CD235a (glycophorin A) and CD235b (glycophorin B), homologous type I sialoglycoproteins of the erythrocyte (red blood cell) membrane that bear the antigenic determinants for the MN and Ss blood groups. CD235ab is expressed on early- and late-stage erythroblasts, mature erythrocytes, and erythroid cell lines such as K562 and HEL, but not on other cell types. CD235a is abundantly expressed whereas CD235b is a relatively minor membrane component. The proteins are believed to provide a large mucin-like surface to erythrocytes that acts to minimize aggregation in the circulation. The HIR2 antibody binds with higher affinity to CD235a than CD235b, and agglutinates untreated erythrocytes.

Target Antigen Name:	CD235ab (Glycophorin A/B)
Alternative Names:	CD235a, CD235ab, CD235b, Glycophorin A, Glycophorin B, GPA, GPB, GYPA, GYPB, MN sialoglycoprotein, PAS-2, PAS-3, Sialoglycoprotein alpha, Sialoglycoprotein delta, SS-active sialoglycoprotein
Gene ID:	2993/2994
Species Reactivity:	Human
Host Species:	Mouse
Clonality:	Monoclonal
Clone:	HIR2 (GA-R2)
Isotype:	IgG2b, kappa
Immunogen:	Synthetic peptide corresponding to N-terminal region of human CD235ab
Conjugate:	FITC

## Applications


Verified:	FC
Reported:	FC
Special Applications:	This antibody clone has been verified for purity assessments of cells isolated with EasySep™ kits, including EasySep™ Human Glycophorin A Depletion Kit (Catalog #18352).

Abbreviations: CellSep: Cell separation; ChIP: Chromatin immunoprecipitation; FA: Functional assay; FACS: Fluorescence activated cell sorting; FC: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence microscopy; IHC: Immunohistochemistry; IP: Immunoprecipitation; RIA: Radioimmunoassay; WB: Western blotting

## Properties

Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Purification:	The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
Stability and Storage:	Product stable at 2 - 8°C when stored undiluted. Do not freeze. Protect product from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com.
Directions for Use:	For flow cytometry the suggested use of this antibody is ≤ 0.2 µg per 1 x 10 <sup>6</sup> cells in 100 µL volume. It is recommended that the antibody be titrated for optimal performance for each application.

## Data



Flow cytometry analysis of human whole blood labeled with Anti-Human CD235ab (Glycophorin A/B) Antibody, Clone HIR2, FITC (filled histogram) or Mouse IgG2b, kappa Isotype Control Antibody, Clone MPC-11, FITC (Catalog #60072FI) (solid line histogram).

## Related Products

For a complete list of antibodies, including other conjugates, sizes and clones, as well as related products available from STEMCELL Technologies, please visit our website at [www.stemcell.com/antibodies](http://www.stemcell.com/antibodies) or contact us at [techsupport@stemcell.com](mailto:techsupport@stemcell.com).

## References

1. Corces-Zimmerman MR et al. (2014) Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. *Proc Natl Acad Sci USA* 111(7): 2548–53. (FC)
2. Headland SE et al. (2014) Cutting-edge analysis of extracellular microparticles using ImageStream(X) imaging flow cytometry. *Sci Rep* 4: 5237. (FC)
3. Kamat V et al. (2014) MicroRNA screen of human embryonic stem cell differentiation reveals miR-105 as an enhancer of megakaryopoiesis from adult CD34+ cells. *Stem Cells* 32(5): 1337–46. (FC)
4. Manfrini M et al. (2013) Mesenchymal stem cells from patients to assay bone graft substitutes. *J Cell Physiol* 228(6): 1229–37. (FC)
5. Paluru P et al. (2013) The negative impact of wnt signaling on megakaryocyte and primitive erythroid progenitors derived from human embryonic stem cells. *Stem Cell Res* 12(2): 441–51. (FC)
6. Soderblom EJ et al. (2013) Proteomic analysis of ERK1/2-mediated human sickle red blood cell membrane protein phosphorylation. *Clin Proteomics* 10(1): 1. (IP, WB)
7. Gros A et al. (2012) Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. *Clin Cancer Res* 18(19): 5212–23. (FC)
8. MacLean G a. et al. (2012) Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. *Proc Natl Acad Sci USA* 109(43): 17567–72. (FC)
9. Wong S et al. (2010) Establishment of an erythroid cell line from primary CD36+ erythroid progenitor cells. *Exp Hematol* 38(11): 994–1005.e1-2. (FC)
10. Chen Q et al. (2009) Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. *Proc Natl Acad Sci USA* 106(51): 21783–8. (FC)
11. Choi K-D et al. (2009) Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. *Stem Cells* 27(3): 559–67. (FC)
12. Thorogate R et al. (2008) A novel fluorescence-based method in forensic science for the detection of blood in situ. *Forensic Sci Int Genet* 2(4): 363–71. (ICC, IF)

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2017 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, Scientists Helping Scientists, EasySep, and RoboSep are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.